Skip to content

Effect of Aggressive Warming versus Routine Thermal Management on the Perioperative Electroencephalography and Postoperative Cognitive Function in Elderly Patients Undergoing Total hip arthroplasty a single-center randomized controlled trial

Effect of Aggressive Warming versus Routine Thermal Management on the Perioperative Electroencephalography and Postoperative Cognitive Function in Elderly Patients Undergoing Total hip arthroplasty a single-center randomized controlled trial

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400093076
Enrollment
Unknown
Registered
2024-11-28
Start date
2024-12-01
Completion date
Unknown
Last updated
2024-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

perioperative neurocognitive disorders

Interventions

Group A (routine care group):routine care intraoperative
Group B(aggressive warming group):inflatable heating blankets

Sponsors

Department of Anesthesiology, Xuzhou Central Hospital, Xuzhou 221009, Jiangsu, China.
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1Age 65-90 years; 2ASA I-III; 3Patients with preoperative MMSE score >23 and without fever; 4Planned Total hip arthroplasty under general anesthesia; 5Patients volunteered to be tested and signed an informed consent form.

Exclusion criteria

Exclusion criteria: 1Pre-operative cognitive dysfunction, mental or psychological diseases; 2Serious abnormalities of liver and kidney function; 3Diabetic patients with diabetes mellitus complications; 4Unstable angina pectoris, myocardial infarction, and any cerebrovascular accidents such as stroke, or transient ischaemic attack (TIA) within 3 months; 5Blood pressure = 180/110 mm Hg at preoperative visit; 6 Those who are determined/suspected to have abused or long-term application of narcotic sedative analgesics; 7Those who have taken hormones or other immunosuppressive drugs for >10 days within 6months or have a history of adrenocortical suppression or have an immune system disorder; 8Those who suffer from hyper- or hypothyroidism, rheumatism and other diseases; 9Patients with serious infectious diseases that cause elevated body temperature; 10Those who will be operated again within 3 months; 11Patients participating in other studies within 30 days.

Design outcomes

Primary

MeasureTime frame
Incidence of dNCR at 7 days postoperatively;

Secondary

MeasureTime frame
Incidence of POCD at 1 and 3 months ;Peripheral blood levels of L-6, S-100ß, Aß, Tau, pTau;

Countries

China

Contacts

Public ContactKai Wang

Department of Anesthesiology, Xuzhou Central Hospital, Xuzhou 221009, Jiangsu, China.

wangkaistream99@sina.com+86 181 1201 2729

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026